Despite advances in surgery and chemotherapy over the past 20 years, only modest progress has been made in improving overall survival in patients with ovarian cancer. (cancerresearch.org)
However, the therapy did not improve overall survival and it did not work if the cancer had spread to other parts of the body, the agency noted. (health.com)
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time at the ESMO 2016 Congress in Copenhagen. (sciencedaily.com)